DURECT Corporation
Index- P/E- EPS (ttm)-0.16 Insider Own0.20% Shs Outstand227.69M Perf Week4.40%
Market Cap90.97M Forward P/E- EPS next Y-0.16 Insider Trans366.49% Shs Float224.52M Perf Month-6.72%
Income-37.00M PEG- EPS next Q-0.05 Inst Own52.50% Short Float6.50% Perf Quarter-40.67%
Sales13.70M P/S6.64 EPS this Y-124.20% Inst Trans0.31% Short Ratio17.70 Perf Half Y-63.21%
Book/sh0.21 P/B1.94 EPS next Y5.60% ROA-39.30% Target Price5.67 Perf Year-76.26%
Cash/sh0.29 P/C1.42 EPS next 5Y15.00% ROE-60.90% 52W Range0.37 - 1.85 Perf YTD-58.58%
Dividend- P/FCF- EPS past 5Y9.10% ROI-43.70% 52W High-77.86% Beta1.48
Dividend %- Quick Ratio7.60 Sales past 5Y-0.10% Gross Margin85.80% 52W Low11.58% ATR0.05
Employees78 Current Ratio7.80 Sales Q/Q-13.60% Oper. Margin- RSI (14)43.69 Volatility11.66% 12.91%
OptionableYes Debt/Eq0.00 EPS Q/Q-2.20% Profit Margin- Rel Volume1.11 Prev Close0.41
ShortableYes LT Debt/Eq0.44 EarningsMay 04 AMC Payout- Avg Volume824.22K Price0.41
Recom1.70 SMA20-4.59% SMA50-20.82% SMA200-55.29% Volume915,174 Change-1.28%
Oct-30-20Initiated Chardan Capital Markets Buy $7
Oct-12-20Initiated ROTH Capital Buy
Jul-31-20Initiated Oppenheimer Outperform $7
Jan-31-20Initiated B. Riley FBR Buy $5
Nov-18-19Resumed Cantor Fitzgerald Overweight
Sep-06-19Initiated Cantor Fitzgerald Overweight $5
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Jul-12-17Upgrade Stifel Hold → Buy $1.25 → $3
Feb-28-17Resumed H.C. Wainwright Buy $3
Apr-25-16Initiated Rodman & Renshaw Buy $4
May-01-15Reiterated Stifel Buy $1.50 → $2.50
May-01-15Reiterated Cantor Fitzgerald Buy $2.50 → $3
Mar-25-13Initiated Stifel Buy $3
Nov-01-12Downgrade C.K. Cooper Buy → Hold $3
Aug-17-12Initiated C.K. Cooper Buy $3
Jun-23-09Initiated Caris & Company Buy $5
Mar-26-09Initiated Wedbush Morgan Hold
May-18-22 01:53PM  
May-08-22 08:19AM  
May-04-22 06:25PM  
Apr-27-22 04:15PM  
Mar-24-22 09:30AM  
Mar-23-22 04:15PM  
Mar-09-22 04:30PM  
Mar-07-22 05:25PM  
Mar-01-22 08:30AM  
Feb-28-22 04:30PM  
Jan-13-22 10:00AM  
Jan-06-22 04:05PM  
Dec-22-21 07:30AM  
Dec-14-21 09:00AM  
Nov-29-21 09:00AM  
Nov-12-21 09:00AM  
Nov-10-21 09:00AM  
Nov-08-21 09:00AM  
Nov-07-21 07:45AM  
Nov-02-21 06:15PM  
Oct-26-21 09:00AM  
Oct-25-21 03:01PM  
Oct-07-21 09:00AM  
Sep-23-21 09:00AM  
Sep-15-21 09:00AM  
Sep-07-21 09:00AM  
Aug-09-21 05:29AM  
Jul-29-21 07:25PM  
Jul-22-21 08:30AM  
Jul-14-21 04:30PM  
Jun-25-21 09:37AM  
Jun-23-21 09:00AM  
Jun-09-21 09:00AM  
May-04-21 07:45PM  
Apr-27-21 08:30AM  
Mar-09-21 09:00AM  
Mar-04-21 05:31PM  
Mar-03-21 06:02PM  
Feb-04-21 09:18AM  
Feb-03-21 04:01PM  
Feb-02-21 08:28AM  
Jan-25-21 08:30AM  
Jan-05-21 08:30AM  
Jan-04-21 08:30AM  
Dec-21-20 08:30AM  
Dec-16-20 08:30AM  
Dec-09-20 01:33PM  
Dec-07-20 11:15AM  
Nov-13-20 09:00AM  
Nov-10-20 08:30AM  
Nov-02-20 11:31PM  
Oct-27-20 08:30AM  
Oct-26-20 04:30PM  
Oct-05-20 08:30AM  
Sep-30-20 04:53PM  
Sep-23-20 08:30AM  
Sep-22-20 08:30AM  
Sep-10-20 08:30AM  
Aug-27-20 08:30AM  
Aug-26-20 04:30PM  
Aug-05-20 03:31PM  
Aug-04-20 01:00AM  
Aug-03-20 06:35PM  
Jul-28-20 08:30AM  
Jul-07-20 07:35AM  
Jul-01-20 08:30AM  
Jun-29-20 09:00AM  
Jun-26-20 05:15PM  
Jun-11-20 02:45PM  
May-28-20 09:00AM  
May-26-20 08:30AM  
May-20-20 10:04AM  
May-12-20 03:00PM  
May-11-20 06:55PM  
May-04-20 05:00PM  
Apr-28-20 12:33PM  
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Gilead Sciences, Inc. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Farfel Gail MDirectorMay 18Buy0.4129,91112,201100,000May 18 08:35 PM
AZAB MOHAMMADDirectorMay 17Buy0.4220,0008,40730,000May 18 08:05 PM
Farfel Gail MDirectorMay 16Buy0.3925,3009,81170,089May 18 08:35 PM
AZAB MOHAMMADDirectorMay 16Buy0.3810,0003,76710,000May 18 08:05 PM
Farfel Gail MDirectorMay 13Buy0.409,2503,70044,789May 13 09:07 PM
Farfel Gail MDirectorMay 12Buy0.391,50058535,539May 13 09:07 PM
Farfel Gail MDirectorMay 11Buy0.409,9503,97334,039May 13 09:07 PM
Farfel Gail MDirectorMay 10Buy0.412,33995024,089May 12 08:32 PM
Farfel Gail MDirectorMay 10Buy0.404,2501,67921,750May 10 09:12 PM
Farfel Gail MDirectorMay 09Buy0.3917,5006,90617,500May 10 09:12 PM
Robertson Judith J.DirectorMar 14Buy0.59200,000118,000200,000Mar 16 01:41 PM
BENITO SIMON XDirectorDec 07Buy1.0220,00020,360105,000Dec 09 01:35 PM